These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 18809839)

  • 1. Hyposmia in G2019S LRRK2-related parkinsonism: clinical and pathologic data.
    Silveira-Moriyama L; Guedes LC; Kingsbury A; Ayling H; Shaw K; Barbosa ER; Bonifati V; Quinn NP; Abou-Sleiman P; Wood NW; Petrie A; Sampaio C; Ferreira JJ; Holton J; Revesz T; Lees AJ
    Neurology; 2008 Sep; 71(13):1021-6. PubMed ID: 18809839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olfactory dysfunction in LRRK2 G2019S mutation carriers.
    Saunders-Pullman R; Stanley K; Wang C; San Luciano M; Shanker V; Hunt A; Severt L; Raymond D; Ozelius LJ; Lipton RB; Bressman SB
    Neurology; 2011 Jul; 77(4):319-24. PubMed ID: 21753159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonmotor symptoms in LRRK2 G2019S associated Parkinson's disease.
    Gaig C; Vilas D; Infante J; Sierra M; García-Gorostiaga I; Buongiorno M; Ezquerra M; Martí MJ; Valldeoriola F; Aguilar M; Calopa M; Hernandez-Vara J; Tolosa E
    PLoS One; 2014; 9(10):e108982. PubMed ID: 25330404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olfaction and imaging biomarkers in premotor LRRK2 G2019S-associated Parkinson disease.
    Sierra M; Sánchez-Juan P; Martínez-Rodríguez MI; González-Aramburu I; García-Gorostiaga I; Quirce MR; Palacio E; Carril JM; Berciano J; Combarros O; Infante J
    Neurology; 2013 Feb; 80(7):621-6. PubMed ID: 23325906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olfactory heterogeneity in LRRK2 related Parkinsonism.
    Silveira-Moriyama L; Munhoz RP; de J Carvalho M; Raskin S; Rogaeva E; de C Aguiar P; Bressan RA; Felicio AC; Barsottini OG; Andrade LA; Chien HF; Bonifati V; Barbosa ER; Teive HA; Lees AJ
    Mov Disord; 2010 Dec; 25(16):2879-83. PubMed ID: 20818658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olfactory deficits and cardiac 123I-MIBG in Parkinson's disease related to the LRRK2 R1441G and G2019S mutations.
    Ruiz-Martínez J; Gorostidi A; Goyenechea E; Alzualde A; Poza JJ; Rodríguez F; Bergareche A; Moreno F; López de Munain A; Martí Massó JF
    Mov Disord; 2011 Sep; 26(11):2026-31. PubMed ID: 21611983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olfactory dysfunction in sporadic Parkinson's Disease and LRRK2 carriers.
    Johansen KK; Warø BJ; Aasly JO
    Acta Neurol Scand; 2014 May; 129(5):300-6. PubMed ID: 23937295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Olfactory Performance With Motor Decline and Age at Onset in People With Parkinson Disease and the
    Saunders-Pullman R; Ortega RA; Wang C; Raymond D; Elango S; Leaver K; Urval N; Katsnelson V; Gerber R; Swan M; Shanker V; Alcalay RN; Mirelman A; Brumm MC; Mejia-Santana H; Coffey CS; Marek K; Ozelius LJ; Giladi N; Marder KS; Bressman SB
    Neurology; 2022 Aug; 99(8):e814-e823. PubMed ID: 35995594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.
    Illarioshkin SN; Shadrina MI; Slominsky PA; Bespalova EV; Zagorovskaya TB; Bagyeva GKh; Markova ED; Limborska SA; Ivanova-Smolenskaya IA
    Eur J Neurol; 2007 Apr; 14(4):413-7. PubMed ID: 17388990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect?
    Orr-Urtreger A; Shifrin C; Rozovski U; Rosner S; Bercovich D; Gurevich T; Yagev-More H; Bar-Shira A; Giladi N
    Neurology; 2007 Oct; 69(16):1595-602. PubMed ID: 17938369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis.
    Agalliu I; San Luciano M; Mirelman A; Giladi N; Waro B; Aasly J; Inzelberg R; Hassin-Baer S; Friedman E; Ruiz-Martinez J; Marti-Masso JF; Orr-Urtreger A; Bressman S; Saunders-Pullman R
    JAMA Neurol; 2015 Jan; 72(1):58-65. PubMed ID: 25401981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A clinical, neuropsychological and olfactory evaluation of a large family with LRRK2 mutations.
    Lohmann E; Leclere L; De Anna F; Lesage S; Dubois B; Agid Y; Dürr A; Brice A;
    Parkinsonism Relat Disord; 2009 May; 15(4):273-6. PubMed ID: 18718805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies.
    Gaig C; Martí MJ; Ezquerra M; Rey MJ; Cardozo A; Tolosa E
    J Neurol Neurosurg Psychiatry; 2007 Jun; 78(6):626-8. PubMed ID: 17210620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic screening for the LRRK2 R1441C and G2019S mutations in Parkinsonian patients from Campania.
    De Rosa A; De Michele G; Guacci A; Carbone R; Lieto M; Peluso S; Picillo M; Barone P; Salemi F; Laiso A; Saccà F; Tessitore A; Pellecchia MT; Bonifati V; Criscuolo C
    J Parkinsons Dis; 2014; 4(1):123-8. PubMed ID: 24496098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical molecular genetics for PARK8 (LRRK2)].
    Tomiyama H; Hatano T; Hattori N
    Brain Nerve; 2007 Aug; 59(8):839-50. PubMed ID: 17713120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers.
    Marras C; Schüle B; Munhoz RP; Rogaeva E; Langston JW; Kasten M; Meaney C; Klein C; Wadia PM; Lim SY; Chuang RS; Zadikof C; Steeves T; Prakash KM; de Bie RM; Adeli G; Thomsen T; Johansen KK; Teive HA; Asante A; Reginold W; Lang AE
    Neurology; 2011 Jul; 77(4):325-33. PubMed ID: 21753163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease.
    Clark LN; Wang Y; Karlins E; Saito L; Mejia-Santana H; Harris J; Louis ED; Cote LJ; Andrews H; Fahn S; Waters C; Ford B; Frucht S; Ottman R; Marder K
    Neurology; 2006 Nov; 67(10):1786-91. PubMed ID: 17050822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases.
    Mamais A; Raja M; Manzoni C; Dihanich S; Lees A; Moore D; Lewis PA; Bandopadhyay R
    Neurobiol Dis; 2013 Oct; 58():183-90. PubMed ID: 23747310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical heterogeneity of the LRRK2 G2019S mutation.
    Papapetropoulos S; Singer C; Ross OA; Toft M; Johnson JL; Farrer MJ; Mash DC
    Arch Neurol; 2006 Sep; 63(9):1242-6. PubMed ID: 16966501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subclinical signs in LRRK2 mutation carriers.
    Johansen KK; White LR; Farrer MJ; Aasly JO
    Parkinsonism Relat Disord; 2011 Aug; 17(7):528-32. PubMed ID: 21641848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.